Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18739558 | 0.90 | MAPT (0.54) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL18739546 | 0.89 | MAPT (0.53) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL28812695 | 0.88 | GPR119 (0.54) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL17856627 | 0.87 | P2RX7 (0.49) | MAPTSMN1; SMN2GPR119THRBSTS | |
| SCHEMBL3467159 | 0.84 | GPR119 (0.51) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL18739577 | 0.82 | GPR119 (0.50) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL17223024 | 0.81 | RBP4 (0.50) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL19405061 | 0.81 | GPR119 (0.52) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL2103090 | 0.81 | THRB (0.48) | MAPTSMN1; SMN2GPR119THRBTP53 | |
| SCHEMBL17222912 | 0.80 | MAPT (0.51) | MAPTSMN1; SMN2GPR119THRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359533-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3472160-B1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-04 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017060406-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | MAPT 3194/4885SMN1; SMN2 4806/4885GPR119 1412/4885 |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | MAPT 3973/4885SMN1; SMN2 4794/4885GPR119 1212/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | MAPT 3194/4885SMN1; SMN2 4806/4885GPR119 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.